JRJay Ramchand

Jay Ramchand

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jay Ramchand has a total of 212 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Left ventricular hypertrophy, brain atrophy and cognitive decline in type 2 diabetes mellitus: Diabetes & Dementia (D2) cohort study

    by Amy Brodtmann, Sheila K Patel, Carolina Restrepo, Mohamed Salah Khlif, Emilio Werden, Rachel Ellis, Shahad Alsawaf, Elif Ekinci, Piyush M Srivastava, Jay Ramchand, et al.

    BACKGROUND: People with type 2 diabetes mellitus (T2DM) are at higher risk of cerebral small vessel disease and left ventricular hypertrophy (LVH), potentially contributing to cognitive decline and dementia. We aimed to describe brain volume and cognitive trajectories over 2 years in a cohort of people with T2DM and to determine whether LVH causes increased brain atrophy and cognitive decline. METHODS: Diabetes and Dementia (D2) study is a multicentre observational cohort study in Melbourne, Australia. Participants aged >50 years were recruited via 2 hospital outpatient clinics, 3 private clinics, and study advertisements. Participants with pre-existing cognitive impairment, life-limiting medical illness, and severe chronic renal impairment were excluded. Participants attended study visits for brain MRI, transthoracic echocardiography (TTE), and cognitive testing at baseline and 2 years. The exposure was LVH determined on baseline TTE. Pre-specified outcomes were total brain volume (TBV) change and cognitive decline (z-score change≤-1 in any cognitive domain) over 2 years. Regression analyses examined associations between baseline variables and outcomes. A causal inference approach was utilized using inverse probability of treatment weighting to standardize for confounding covariates, excluding participants for non-positivity on age and baseline TBV. RESULTS: Participants were recruited 20May2016 to 20March2020: 2378 screened, 702 eligible, 196 consented, 150 baseline and 123 2-year assessments with complete MRI, TTE, and cognitive data (17.4% attrition). At baseline, LVH was associated with female sex, older age, lower educational attainment, lower mood, hypertension, obesity, beta-blocker use, and smaller TBV. Participants with baseline cognitive impairment exhibited greater brain atrophy. Lower educational attainment, hypertension, and lower baseline cognitive scores were associated with cognitive decline. Causal inference analysis included 62 participants with no LVH (20(32%) women; mean [SD]=66.9[5.9] years), and 31 with LVH (17(55%) women, 67.4[5.4] years). LVH caused lower TBV change: standardized mean difference (95% CI) 6.3 (0.1, 12.5) cm 3 , P = .048. LVH had no effect on cognitive decline. CONCLUSIONS: Brain atrophy and cognitive decline were associated with baseline cognitive impairment. LVH caused less brain atrophy and cognitive decline in people with T2DM. We conclude that guideline-directed LVH therapies such as beta-blockers have both cardioprotective (remodelling) and neuroprotective effects. TRIAL REGISTRATION: ACTRN12616000546459 UTN: U1111-1181-6659 Clinical perspective: What is new?: Causal inference modelling was used to ask whether left ventricular hypertrophy (LVH) caused increased brain atrophy and cognitive decline over 2 years LVH reversed in 40% of participants Increased brain atrophy was associated with baseline cognitive impairment Lower educational attainment, baseline cognitive scores and hypertension were associated with cognitive decline LVH caused less brain atrophy with no effect on cognitive decline What are the clinical implications?: LVH therapies, especially â-blockers, may have both cardioprotective (remodelling) and neuroprotective effects Cognitive impairment in people with T2DM should prompt aggressive risk factor management to prevent brain atrophy and cognitive decline

  • Incremental prognostic value of late gadolinium enhancement in hypertrophic cardiomyopathy in a large contemporary cohort

    by Susan K Keen, Stuti Shah, Hesham Sheashaa, Mohammed Abusafia, Shada Jadam, Simrat Kaur, Andrew Gaballa, Susan Ospina, Katy Rutkowski, Jay Ramchand, et al.

    Aims: Extensive late gadolinium enhancement (LGE) is recognized in contemporary hypertrophic cardiomyopathy (HCM) risk assessment, but the prognostic value of lower quantitative thresholds remains debated. We aimed to evaluate whether quantitative LGE provides independent and incremental prognostic information beyond established clinical and phenotypic risk markers. Methods and results: This large contemporary cohort included 3035 patients (median age 58 years, 57% men); 56% had LGE, including 242 (8%) with LGE > 10%. Most patients have obstructive hypertrophic cardiomyopathy (71%), 1498 (69%) of which subsequently underwent septal reduction therapy at a median of 43 days [interquartile range (IQR) 5–107) from the cardiac magnetic resonance (CMR) date (1485 myectomies and 13 alcohol septal ablations). Over a median of 8.8 years, 331 (11%) primary endpoints occurred [295 cardiovascular deaths (9.7%) and 36 appropriate implantable cardioverter–defibrillator discharges (1.3%)]. On multivariable Cox proportional hazards analysis [adjusted for standard clinical and CMR variables, higher %LGE (1.05 per 1% increase, 95% confidence interval 1.03–1.06; P < 0.001)] was associated with primary events. Compared with no LGE, LGE ≥10% was associated with higher risk of the composite endpoint. Conclusion: In this large contemporary HCM cohort, quantitative LGE was independently associated with long-term adverse outcomes. LGE ≥10% identified patients at significantly higher risk, and incorporation of LGE improved discrimination beyond ESC and AHA/ACC risk assessment.

  • Open Access

    Distribution of peri-device leaks on transoesophageal echocardiography and cardiac computed tomography after WATCHMAN implantation: a multicentre core-lab analysis

    by Issam Motairek, Mohamad Mdaihly, Walid Saliba, Andrea Natale, Rodney Horton, Devi Nair, Bradley J Mikaelian, Manish Shah, Ashish Sadhu, Kathy Wolsky, et al.

  • Open Access

    Prognostic value of compact myocardial thinning in patients with left ventricular non-compaction

    by Tea Gegenava, Martijn Tukker, Kadir Caliskan, Alexander Hirsch, Ashish Manohar, Seung-Pyo Lee, Anjali T. Owens, Deborah H. Kwon, Jay Ramchand, Matthew T. Wheeler, et al.

    Introduction: Left ventricular non-compaction (LVNC) can be associated with a wide spectrum of clinical presentations, ranging from asymptomatic to ventricular tachyarrhythmia (VT), heart failure (HF), and cerebrovascular accidents (CVA). In this multicenter study, we explored the associations between clinical and imaging characteristics and outcomes of patients with LVNC, and externally validated the predictive value of myocardial thinning identified on cardiac magnetic resonance imaging (CMR) as previously described. Methods: 214 adult patients (54% male, mean age 41±16 years) meeting the imaging criteria for LVNC were identified. Baseline clinical data, echocardiographic findings, and CMR characteristics were analyzed. Long-axis balanced steady-state free precession CMR sequences were used to assess myocardial thickness. Myocardial thinning was defined as a 50% or greater diameter reduction of the compacted myocardium compared to a contiguous segment. The primary endpoint was a composite of all-cause mortality, HF hospitalization, need of left ventricular assist device (LVAD) or heart transplant, cardiac resynchronization therapy (CRT), CVA/transient ischemic attacks (TIA), and VT and appropriate implantable cardioverter defibrillator (ICD) therapy. Results: Focal myocardial thinning was observed in 42 patients (20%). Over a median follow-up period of 7 years (IQR, 4–10 years), 54 patients (24%) experienced a primary outcome (including all-cause mortality n=15 (7%), HF hospitalization/CRT n=33 (15%), CVA/TIA n=10 (5%), VT and appropriate ICD therapy n=14 (7%), LVAD/heart transplant n=3 (1.4%). Patients with myocardial thinning had more cumulative adverse events compared to those without myocardial thinning (chi-square = 29.516, log-rank < 0.001), even after matching for medical risk score. In a multivariate Cox regression model, myocardial thinning remained associated with outcomes: HR 3.052(95% CI: 1.569-5.937, p=0.001). When evaluating the incremental prognostic value of myocardial thinning over clinical and imaging characteristics, we observed that adding myocardial thinning added value to prediction models that included clinical and imaging features. Conclusions: The presence of myocardial thinning is associated with adverse cardiovascular events in adult LVNC patients. Along with the medical risk score and other imaging variables, this feature enhances the risk stratification of individuals with LVNC. Incorporating myocardial thinning into medical risk assessments can improve the prediction and management of adverse outcomes in these patients.

  • Open Access

    Comparative Analysis of Chat‐Based Artificial Intelligence Models in Addressing Common and Challenging Valvular Heart Disease Clinical Scenarios

    by Joseph Kassab, Vishwum Kapadia, Christopher Massad, Ashish Sarraju, Jay Ramchand, Samir R. Kapadia, Serge C. Harb


  • Vulnerability to environmental and climatic health provocations among women and men hospitalized with chronic heart disease: insights from the RESILIENCE TRIAL cohort

    by Simon Stewart, Sheila K Patel, Terase F Lancefield, Thalys S Rodrigues, Nicholas Doumtsis, Ashleigh Jess, Emily-Rose Vaughan-Fowler, Yih-Kai Chan, Jay Ramchand, Paul A Yates, et al.

    Aims: We aimed to recruit a representative cohort of women and men with multi-morbid chronic heart disease as part of a trial testing an innovative, nurse-co-ordinated, multi-faceted intervention to lower rehospitalization and death by addressing areas of vulnerability to external challenges to their health. Methods and results: The prospective, randomized open, blinded end-point RESILIENCE Trial recruited 203 hospital inpatients (mean age 75.7 ± 10.2 years) of whom 51% were women and 94% had combined coronary artery disease, heart failure, and/or atrial fibrillation. Levels of concurrent multi-morbidity were high (mean Charlson Index of Comorbidity Score 6.5 ± 2.7), and 8.9% had at least mild frailty according to the Rockwood Clinical Frailty Scale. Including the index admission, 19–20% of women and men had a pre-existing pattern of seasonally linked hospitalization (seasonality). Detailed phenotyping revealed that 48% of women and 40% of men had ≥3 physiological factors, and 15% of women and 16% of men had ≥3 behavioural factors likely to increase their vulnerability to external provocations to their health. Overall, 61–62% of women and men had ≥4 combined factors indicative of such vulnerability. Additional factors such as reliance on the public health system (63 vs. 49%), lower education (30 vs. 14%), and living alone (48 vs. 29%) were more prevalent in women. Conclusion: We successfully recruited women and men with multi-morbid chronic heart disease and bio-behavioural indicators of vulnerability to external provocations to their health. Once completed, the RESILIENCE TRIAL will provide important insights on the impact of addressing such vulnerability (promoting resilience) on subsequent health outcomes. Registration: ClinicalTrials.org: NCT04614428.


  • Effect of Myocardial Tissue Characterization Using Native T1 to Predict the Occurrence of Adverse Events in Patients With Chronic Kidney Disease and Severe Aortic Stenosis

    by Jay Ramchand, Jean-Pierre Iskandar, Habib Layoun, Rishi Puri, Michael Chetrit, Louise M. Burrell, Amar Krishnaswamy, Brian P. Griffin, James J. Yun, Scott D. Flamm, et al.


  • Open Access

    Depressed Right Ventricular Systolic Function in Heart Failure Due to Constrictive Pericarditis

    by Veena Raizada, Kimi Sato, Alaa Alashi, Arnav Kumar, Deborah Kwon, Jay Ramchand, Amy Dillenbeck, Ross E. Zumwalt, Adarsh S. Vangala, Tyler D. Earley, et al.

    Aims: Heart failure in constrictive pericarditis (CP) is attributed to impaired biventricular diastolic filling. However, diseases that cause CP due to myocardial infiltration and fibrosis can also impair biventricular systolic function (sf) and contribute to heart failure. This study of patients with CP examined biventricular sf and the effect of myocardial infiltration by pericardial diseases and the resulting fibrosis on ventricular sf. Methods and results: Histopathologic examinations of right ventricular (RV) and left ventricular (LV) myocardia and pericardia were performed on three autopsied hearts of patients with pericardial diseases. Additionally, in 40 adults with clinical heart failure and 40 healthy adults (controls), sf of both ventricles was examined by echocardiography, including strain measurements, and biventricular diastolic filling and pulmonary artery pressures were assessed by cardiac catheterization. Cardiac histopathology indicated thickening of the pericardium with fibrosis, disease infiltrating the myocardium, greater infiltration of the RV than the LV, and an association of pericardial thickness with myocardial infiltrations. Functional analysis indicated that RVsf was impaired on all echo indices, including strain measurement, but LVsf was preserved. Conclusions: Diseases causing CP are not restricted to the pericardium but also infiltrate the biventricular myocardium and affect the thin-walled RV more than the thick-walled LV, resulting in depressed RVsf. The present results help explain clinical heart failure in the presence of restricted diastolic filling in CP. Depression of RVsf due to progression of fibrosis in the RV myocardium may increase the risk of delayed pericardiectomy.


  • MYOCARDIAL TISSUE CHARACTERIZATION USING NATIVE T1 TIME PREDICTS THE OCCURRENCE OF ADVERSE EVENTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND SEVERE AORTIC STENOSIS

    by Jay Ramchand, Jean-Pierre Iskandar, Rishi Puri, Michael Chetrit, Louise Burrell, Amar Krishnaswamy, Brian Griffin, James Yun, Scott Flamm, Samir Kapadia, et al.